Article
Clinical Neurology
Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, David Lukacsovich, Achintya Varma, X. Steven Chen, Eden R. Martin, Lily Wang
Summary: This study demonstrates the association between DNA methylation (DNAm) in blood and cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD). The findings suggest that changes in pathological processes in the CSF can be reflected in the blood epigenome, providing valuable insights for mechanistic and biomarker studies of AD.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Medicine, Research & Experimental
Juan Lantero-Rodriguez, Anniina Snellman, Andrea L. Benedet, Marta Mila-Aloma, Elena Camporesi, Laia Montoliu-Gaya, Nicholas J. Ashton, Agathe Vrillon, Thomas K. Karikari, Juan Domingo Gispert, Gemma Salvado, Mahnaz Shekari, Christina E. Toomey, Tammaryn L. Lashley, Henrik Zetterberg, Marc Suarez-Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow
Summary: Alzheimer's disease has a long preclinical phase and requires biomarkers for early pathological changes. P-tau235 may be a key feature and staging biomarker. A new CSF p-tau235 assay shows promise in clinical research.
EMBO MOLECULAR MEDICINE
(2021)
Article
Neurosciences
Ana Baena, Yamile Bocanegra, Valeria Torres, Clara Vila-Castelar, Edmarie Guzman-Velez, Joshua T. Fox-Fuller, Jennifer R. Gatchel, Justin Sanchez, Celina F. Pluim, Liliana Ramirez-Gomez, Jairo Martinez, David Pineda, Francisco Lopera, Yakeel T. Quiroz
Summary: This study found that carriers of ADAD reported higher levels of neuroticism compared to non-carriers. Additionally, neuroticism was positively correlated with entorhinal tau levels only in carriers, suggesting a potential relationship between personality traits and AD pathology in preclinical stages.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Neurosciences
Kok Pin Ng, Hui Chiew, Pedro Rosa-Neto, Nagaendran Kandiah, Zahinoor Ismail, Serge Gauthier
Summary: The review of English-language publications suggests that neuropsychiatric symptoms are associated with higher levels of Aβ, potentially predicting cognitive decline, but the connection with tau pathology remains unclear. Longitudinal studies indicate a relationship between NPS and Aβ over time, with two studies linking cerebrospinal fluid total-tau to increased NPS and metabolic decline. Further research is needed to clarify the relationship between NPS and biomarkers, as well as their contribution to preclinical AD.
TRANSLATIONAL NEURODEGENERATION
(2021)
Article
Clinical Neurology
Hyun-Sik Yang, Can Zhang, Becky C. Carlyle, Sherri Y. Zhen, Bianca A. Trombetta, Aaron P. Schultz, Jeremy J. Pruzin, Colleen D. Fitzpatrick, Wai-Ying W. Yau, Dylan R. Kirn, Dorene M. Rentz, Steven E. Arnold, Keith A. Johnson, Reisa A. Sperling, Jasmeer P. Chhatwal, Rudolph E. Tanzi
Summary: The study found that IL-12p70 and IFN-γ are associated with cognitive decline in cognitively unimpaired elderly, and this association may be related to Aβ levels. This suggests that immune dysregulation plays an important role in early-stage cognitive decline.
ALZHEIMERS & DEMENTIA
(2022)
Article
Clinical Neurology
Francisco Martinez-Dubarbie, Armando Guerra-Ruiz, Sara Lopez-Garcia, Carmen Lage, Marta Fernandez-Matarrubia, Jon Infante, Ana Pozueta-Cantudo, Maria Garcia-Martinez, Andrea Corrales-Pardo, Maria Bravo, Marcos Lopez-Hoyos, Juan Irure-Ventura, Pascual Sanchez-Juan, Maria Teresa Garcia-Unzueta, Eloy Rodriguez-Rodriguez
Summary: This study evaluates the performance of plasma biomarkers of AD using the automated Lumipulse platform in detecting pathological changes in cognitively unimpaired subjects.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jogi, Keith Johnson, Reisa Sperling, Vincent Dore, Colin L. Masters, Christopher Rowe, Denise Visser, Bart N. M. van Berckel, Wiesje M. van der Flier, Suzanne Baker, William J. Jagust, Heather J. Wiste, Ronald C. Petersen, Clifford R. Jack, Oskar Hansson
Summary: Abnormal amyloid and tau PET in cognitively unimpaired individuals is strongly associated with short-term cognitive decline and subsequent development of dementia.
Article
Clinical Neurology
Michael G. Slee, Stephanie R. Rainey-Smith, Victor L. Villemagne, James D. Doecke, Hamid R. Sohrabi, Kevin Taddei, David Ames, Vincent Dore, Paul Maruff, Simon M. Laws, Colin L. Masters, Christopher C. Rowe, Ralph N. Martins, Kirk I. Erickson, Belinda M. Brown
Summary: The study found no significant relationship between habitual physical activity and brain amyloid beta levels in cognitively unimpaired older adults, nor did apolipoprotein E (APOE) ε4 carrier status moderate this relationship.
ALZHEIMERS & DEMENTIA
(2023)
Article
Geriatrics & Gerontology
Dong Hyuk Lee, Sang Won Seo, Jee Hoon Roh, Minyoung Oh, Jungsu S. Oh, Seung Jun Oh, Jae Seung Kim, Yong Jeong
Summary: This study demonstrates the differential effect of cognitive reserve (CR) on clinical progression according to the disease status and the modulating effect on the relationship between brain pathology and cognition. The proposed CR marker is associated with years of education and modulates the effect of pathological burden on cognitive performance.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Geriatrics & Gerontology
Ingmar Skoog, Silke Kern, Jenna Najar, Rita Guerreiro, Jose Bras, Margda Waern, Henrik Zetterberg, Kaj Blennow, Anna Zettergren
Summary: This study found that genetic risk of AD beyond the APOE locus is associated with NfL in individuals without A beta 42 pathology, and with A beta 42 in APOE epsilon 4 carriers, suggesting these associations are driven by different mechanisms in cognitively healthy 70-year olds from the general population.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2021)
Article
Clinical Neurology
Lorenzo Barba, Samir Abu Rumeileh, Giovanni Bellomo, Federico Paolini Paoletti, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Federico Massa, Lorenzo Gaetani, Lucilla Parnetti, Markus Otto
Summary: This study found that beta-syn levels in cerebrospinal fluid (CSF) increase in patients with Alzheimer's disease (AD) in the mild cognitive impairment (MCI) and dementia stages. In contrast, the behavior of other synaptic biomarkers, such as alpha-syn, and biomarkers of neuro-axonal damage, such as NfL and t-tau, is different. CSF beta-syn has the best diagnostic performance for distinguishing pre-AD patients from non-AD patients.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Geriatrics & Gerontology
Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Mira Kang, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Yoosoo Chang, Sang Won Seo
Summary: The prevalence of NAFLD is higher in elderly females than in males, and the association between NAFLD and Aβ deposition shows gender differences. Especially in females, the presence and severity of NAFLD predict increased Aβ deposition.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Article
Clinical Neurology
Heling Chu, Chuyi Huang, Ya Miao, Chenxi Ren, Yihui Guan, Fang Xie, Zhuo Fang, Qihao Guo
Summary: This study aimed to investigate the association between subjective sleep characteristics and plasma Alzheimer's disease biomarkers in older cognitively unimpaired adults with higher amyloid-beta burden. Pittsburgh Sleep Quality Index (PSQI) was used to assess subjective sleep quality. The results showed that sleep duration > 8 h and sleep disturbance were associated with amyloid-beta deposition. Falling asleep at 22:00 to 23:00, higher sleep efficiency, no/mild daytime dysfunction, sleep latency <= 30 min, and good sleep quality were associated with improved AD pathology in participants with amyloid-beta deposition.
JOURNAL OF NEUROLOGY
(2023)
Article
Geriatrics & Gerontology
Jean K. Ho, Daniel A. Nation
Summary: This study operationalized neuropsychological decline in older adults and found that it can predict future dementia, providing valuable information for prognosis and clinical decision-making.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Geriatrics & Gerontology
Rebecca Langhough Koscik, Bruce P. Hermann, Samantha Allison, Lindsay R. Clark, Erin M. Jonaitis, Kimberly D. Mueller, Tobey J. Betthauser, Bradley T. Christian, Lianlian Du, Ozioma Okonkwo, Alex Birdsill, Nathaniel Chin, Carey Gleason, Sterling C. Johnson
Summary: This study found that subtle cognitive decline occurs years before a clinical diagnosis of mild cognitive impairment or dementia due to Alzheimer's disease is made. Operational criteria can detect subclinical decline that may signal Alzheimer's disease or other dementia risk.
FRONTIERS IN AGING NEUROSCIENCE
(2021)
Article
Clinical Neurology
Nicholas J. Ashton, Albert Puig-Pijoan, Marta Mila-Aloma, Aida Fernandez-Lebrero, Greta Garcia-Escobar, Fernando Gonzalez-Ortiz, Przemyslaw R. Kac, Wagner S. Brum, Andrea L. Benedet, Juan Lantero-Rodriguez, Theresa A. Day, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Gallen Triana-Baltzer, Setareh Moughadam, Hartmuth Kolb, Paula Ortiz-Romero, Thomas K. Karikari, Carolina Minguillon, Juan Jose Hernandez Sanchez, Irene Navalpotro-Gomez, Oriol Grau-Rivera, Rosa Maria Manero, Victor Puente-Periz, Rafael de la Torre, Jaume Roquer, Jeff L. Dage, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet
Summary: This study compared the main blood phosphorylated tau immunoassays in a memory clinic population and found that several plasma p-tau biomarkers can be used as stand-alone biomarkers to detect Alzheimer's disease.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Gemma Salvado, Victoria Larsson, Karly A. Cody, Nicholas C. Cullen, Erin M. Jonaitis, Erik Stomrud, Gwendlyn Kollmorgen, Norbert Wild, Sebastian Palmqvist, Shorena Janelidze, Niklas Mattsson-Carlgren, Henrik Zetterberg, Kaj Blennow, Sterling C. Johnson, Rik Ossenkoppele, Oskar Hansson
Summary: The study aimed to determine the optimal combinations of cerebrospinal fluid biomarkers for predicting disease progression in Alzheimer's disease and other neurodegenerative diseases. The results showed that the ratio of phosphorylated tau and A beta 42 alone can accurately predict progression in Alzheimer's disease, and adding neurofilament light improves the prediction of all-cause dementia conversion.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Maria Pascual-Lucas, Jose Antonio Allue, Leticia Sarasa, Noelia Fandos, Sergio Castillo, Jose Terencio, Manuel Sarasa, Juan Pablo Tartari, Angela Sanabria, Lluis Tarraga, Agustin Ruiz, Marta Marquie, Sang Won Seo, Hyemin Jang, Merce Boada
Summary: This study investigates the ability of plasma A beta 42/A beta 40 ratio measured by an antibody-free mass-spectrometric method to detect early pathological changes of Alzheimer's disease (AD). The results show that plasma A beta 42/A beta 40 is significantly correlated with A beta-PET levels and can accurately identify individuals in the earliest stages of AD. Additionally, lower plasma A beta 42/A beta 40 ratio is associated with worse episodic memory performance and increased brain atrophy, and can predict clinical conversion to mild cognitive impairment and longitudinal changes in amyloid deposition and brain atrophy at 2-year follow-up.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Review
Clinical Neurology
Lyduine E. Collij, Gill Farrar, David Vallez Garcia, Ilona Bader, Mahnaz Shekari, Luigi Lorenzini, Hugh Pemberton, Daniele Altomare, Sandra Pla, Mery Loor, Pawel Markiewicz, Maqsood Yaqub, Christopher Buckley, Giovanni B. Frisoni, Agneta Nordberg, Pierre Payoux, Andrew Stephens, Rossella Gismondi, Pieter Jelle Visser, Lisa Ford, Mark Schmidt, Cindy Birck, Jean Georges, Anja Mett, Zuzana Walker, Merce Boada, Alexander Drzezga, Rik Vandenberghe, Bernard Hanseeuw, Frank Jessen, Michael Scholl, Craig Ritchie, Isadora Lopes Alves, Juan Domingo Gispert, Frederik Barkhof, AMYPAD Consortium
Summary: Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium aims to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in AD diagnosis and support clinical trial design. AMYPAD has contributed significantly to understanding of amyloid deposition in the brain and improving measurement methodology. Future steps include integrating and curating available clinical data for wider scientific access.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, General & Internal
Camilla Caprioglio, Federica Ribaldi, Leonie N. C. Visser, Carolina Minguillon, Lyduine E. Collij, Oriol Grau-Rivera, Philip Zeyen, Jose Luis Molinuevo, Juan Domingo Gispert, Valentina Garibotto, Christian Moro, Zuzana Walker, Paul Edison, Jean-Francois Demonet, Frederik Barkhof, Philip Scheltens, Isadora Lopes Alves, Rossella Gismondi, Gill Farrar, Andrew W. Stephens, Frank Jessen, Giovanni B. Frisoni, Daniele Altomare
Summary: Individuals who are amyloid-positive with subjective cognitive decline (SCD+) are at higher risk of developing dementia. The disclosure of a positive amyloid-PET result might have psychological risks, but such change did not reach the threshold for clinical concern.
Article
Clinical Neurology
Alexandra Koenig, N. Linz, E. Baykara, J. Troeger, C. Ritchie, S. Saunders, S. Teipel, S. Koehler, G. Sanchez-Benavides, O. Grau-Rivera, J. D. Gispert, S. Palmqvist, P. Tideman, O. Hansson
Summary: The study aims to validate speech biomarkers for early identification of Alzheimer's disease (AD) using remote telephone screening and advanced machine learning. By comparing speech data from different risk populations across Europe, novel speech markers can be identified. This research provides a tool for screening individuals at risk of dementia and monitoring them over time.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Article
Medicine, Research & Experimental
Gemma Salvado, Rik Ossenkoppele, Nicholas J. Ashton, Thomas G. Beach, Geidy E. Serrano, Eric M. Reiman, Henrik Zetterberg, Niklas Mattsson-Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
Summary: Several promising plasma biomarkers for Alzheimer's disease have been developed, but their neuropathological correlates are not fully understood. This study investigates the associations between multiple plasma biomarkers and amyloid and tau neuropathological measures. The results suggest that plasma p-tau217 and A beta 42/40 might be an optimal combination for assessing Alzheimer's-related pathology.
EMBO MOLECULAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Martina A. Angeles, Federico Migliorelli, Luisa F. Leon Ramirez, Cristina Ros, Andres Perissinotti, Andres Tapias, Sebastian Casanueva-Eliceiry, Jaume Pahisa, Aureli Torne, Sergi Vidal-Sicart, Marta Del Pino, Pilar Paredes
Summary: A study on preoperative lymphatic mapping in patients with intermediate and high-risk endometrial cancer found that younger age, high-volume injection of radiotracer (above 4 mL), and smaller tumor size were associated with a higher success rate of sentinel lymph node preoperative detection.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Anna Brugulat-Serrat, Gonzalo Sanchez-Benavides, Raffaele Cacciaglia, Gemma Salvado, Mahnaz Shekari, Lyduine E. Collij, Christopher Buckley, Bart N. M. van Berckel, Andres Perissinotti, Aida Ninerola-Baizan, Marta Mila-Aloma, Natalia Vilor-Tejedor, Gregory Operto, Carles Falcon, Oriol Grau-Rivera, Eider M. Arenaza-Urquijo, Carolina Minguillon, Karine Fauria, Jose Luis Molinuevo, Marc Suarez-Calvet, Juan Domingo Gispert
Summary: The purpose of this study was to investigate the relationship between regional beta-amyloid (Aβ) accumulation and cognitive decline in middle-aged cognitively unimpaired (CU) individuals and whether it is modulated by the APOE-epsilon 4 allele. The results showed that CU individuals who were APOE-epsilon 4 carriers with positive Aβ PET in regions known to accumulate amyloid at later stages of Alzheimer's disease exhibited a steeper decline in cognitive function. This finding suggests that regional visual reading (VR) of Aβ PET may provide prognostic information about future cognitive decline in individuals at higher risk of developing Alzheimer's disease.
Article
Clinical Neurology
Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat-Serrat, Gonzalo Sanchez-Benavides, Carolina Minguillon, Karine Fauria, Jose Luis Molinuevo, Oriol Grau-Rivera, Armand Gonzalez Escalante, Gwendlyn Kollmorgen, Margherita Carboni, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet, Juan Domingo Gispert
Summary: We studied the role of biomarkers of reactive astrogliosis in the pathogenic cascade of Alzheimer's disease. Various fluid biomarkers were found to influence the progression of the disease, with GFAP mediating the association between soluble and insoluble Aβ, and YKL-40 partly explaining the association between Aβ and downstream tau pathology and neuronal injury.
ALZHEIMERS & DEMENTIA
(2023)
Article
Biochemistry & Molecular Biology
Kanta Horie, Gemma Salvado, Nicolas R. Barthelemy, Shorena Janelidze, Yan Li, Yingxin He, Benjamin Saef, Charles D. Chen, Hong Jiang, Olof Strandberg, Alexa Pichet Binette, Sebastian Palmqvist, Chihiro Sato, Pallavi Sachdev, Akihiko Koyama, Brian A. Gordon, Tammie L. S. Benzinger, David M. Holtzman, John C. Morris, Niklas Mattsson-Carlgren, Erik Stomrud, Rik Ossenkoppele, Suzanne E. Schindler, Oskar Hansson, Randall J. Bateman
Summary: Aggregated insoluble tau is a defining feature of Alzheimer's disease, and there is a need for specific fluid biomarkers to track these tau aggregates. However, current fluid biomarkers are not specific enough. Researchers have identified a new cerebrospinal fluid biomarker, MTBR-tau243, which is specific for insoluble tau aggregates and shows strong associations with tau-positron emission tomography and cognitive measures.
Article
Clinical Neurology
Laura Perez-Carbonell, Jordi Sarto, Carles Gaig, Amaia Munoz-Lopetegi, Raquel Ruiz-Garcia, Laura Naranjo, Josep Maria Auge, Andres Perissinotti, Joan Santamaria, Alex Iranzo, Raquel Sanchez-Valle
Summary: This study evaluated the sleep in three cases of GSS and found that their sleep staging was normal. However, some patients experienced reduced sleep efficiency, confusional arousal, obstructive apneas, and periodic leg movements during sleep.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ana Isabel Garcia-Diez, Xavier Tomas Batlle, Andres Perissinotti, Jaime Isern-Kebschull, Montserrat Del Amo, Juan Carlos Soler, Alvaro Bartolome, Jenny Teresa Bencardino
Summary: Diabetic foot complications are increasingly common and costly worldwide, posing a significant burden on patients. Current imaging methods lack specificity, making it challenging to diagnose superimposed foot infections and other lesions. Advances in radiology and nuclear medicine offer potential solutions, but it is important to understand the strengths and limitations of each modality. This review provides a comprehensive approach to imaging diabetic foot complications, including optimal technical considerations for each technique. Advanced MRI techniques are highlighted for their potential to avoid additional studies and complement conventional MRI.
SEMINARS IN MUSCULOSKELETAL RADIOLOGY
(2023)
Article
Clinical Neurology
Luigi Lorenzini, Silvia Ingala, Lyduine E. Collij, Viktor Wottschel, Sven Haller, Kaj Blennow, Giovanni Frisoni, Gael Chetelat, Pierre Payoux, Pablo Lage-Martinez, Michael Ewers, Adam Waldman, Joanna Wardlaw, Craig Ritchie, Juan Domingo Gispert, Henk J. M. M. Mutsaerts, Pieter Jelle Visser, Philip Scheltens, Betty Tijms, Frederik Barkhof, Alle Meije Wink
Summary: Amyloid-beta accumulation in highly connected brain regions is associated with functional connectivity alterations in the early stages of Alzheimer's disease. Dynamic functional connectivity variations indicate increased regional flexibility and promote functional integration. This study investigates the associations between abnormal cerebrospinal fluid amyloid and static and dynamic properties of functional hubs, and their relationship with cognitive performance in non-demented participants. The results suggest that dynamic eigenvector centrality is an early biomarker of Alzheimer's disease pathology and cognitive decline.
BRAIN COMMUNICATIONS
(2023)